Inj, spesolimab-sbzo, 1 mg
Products billed under this code include Spevigo, Spevigo Pfs.
Payment limit per 1 MG, by effective quarter, 2Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Spevigo, Spevigo Pfs.
Payment limit per 1 MG, by effective quarter, 2Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Spevigo | Boehringer Ingelheim Pharmaceuticals, Inc. | 00597-0035-10 | 900 | $59,155.20 |
| Spevigo | Boehringer Ingelheim Pharmaceuticals, Inc. | 00597-0620-20 | 300 | $19,718.40 |
| Spevigo Pfs | Boehringer Ingelheim Pharmaceuticals, Inc. | 00597-7705-41 | 300 | $19,718.40 |
| Spevigo Pfs | Boehringer Ingelheim Pharmaceuticals, Inc. | 00597-7705-72 | 600 | $39,436.80 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $65.728 | $0.00 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $65.728 | $0.00 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $65.728 | $0.00 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $65.728 | $0.00 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $65.728 | $0.00 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $65.728 | +$4.30 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $61.428 | $0.00 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $61.428 | $0.00 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $61.428 | +$0.01 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $61.418 | +$1.27 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $60.148 | −$0.075 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $60.223 | $0.00 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $60.223 | $0.00 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $60.223 | $0.00 | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $60.223 | – | 1 MG | Inj, spesolimab-sbzo, 1 mg | v1, posted February 23, 2024 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.